as ns 398 vioxx celecoxib p54 etodolac l 804600 and s 33516 paf antagonists such as sr 27417 a 137491 abt 299 apafant bepafant minopafant e 6123 bn 50727 nupafant and modipafant pde iv inhibitors such as ariflo torbafylline rolipram filaminast piclamilast cipamfylline cg 1088 v 11294a ct 2820 pd 168787 cp 293121 dwp 205297 cp 220629 sh 636 bay 19 8004 and roflumilast inhibitors of cytokine production such as inhibitors of the nf u03bab transcription factor or other anti inflammatory agents known to those skilled in the art the concentrations of the anti inflammatory agents contained in the compositions of the present invention will vary based on the agent or agents selected and the type of inflammation being treated the concentrations will be sufficient to reduce inflammation in the targeted ophthalmic otic or nasal tissues following topical application of the compositions to those tissues such an amount is referred to herein as u201c an anti inflammatory effective amount u201d the compositions of the present invention will typically contain one or more anti inflammatory agents in an amount of from about 0 01 to about 1 0 wt the compositions are typically administered to the affected ophthalmic otic or nasal tissues by topically applying one to four drops of a sterile solution or suspension or a comparable amount of an ointment gel or other.